Celiac.com Sponsor (A1):


Join eNewsletter


Celiac.com Sponsor (A1-m):



Join eNewsletter
  • Join Our Community!

    Ask us a question in our celiac / gluten-free forum.

  • Scott Adams

    PD-L1 in Small Bowel Adenocarcinoma More Common in Celiac Patients

    Scott Adams
    0
    Reviewed and edited by a celiac disease expert.

      A team of researchers recently set out to investigate PD-L1 and PD-1 expression in non-hereditary, non-ampullary SBAs, associated with celiac disease.


    Adenocarcinoma of the Sigmoid Colon (en face, closeup). Image: CC BY 2.0--euthman
    Caption: Adenocarcinoma of the Sigmoid Colon (en face, closeup). Image: CC BY 2.0--euthman

    Celiac.com 04/28/2020 - People who suffer from small bowel adenocarcinomas (SBAs) usually have poor outcomes, and face limited treatment options. Programmed cell death protein-1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway blockade is an effective treatment in many micro-satellite instability-high (MSI-H) solid tumors. 

    A team of researchers recently set out to investigate PD-L1 and PD-1 expression in non-hereditary, non-ampullary SBAs, associated with celiac disease, Crohn’s disease, or sporadic, recruited through the Small Bowel Cancer Italian Consortium. 



    Celiac.com Sponsor (A12):






    Celiac.com Sponsor (A12-m):




    The researchers assessed PD-L1 and PD-1 by immunohistochemistry in a series of 121 surgically resected SBAs, including 34 celiac disease-SBAs, 49 CrD-SBAs, and 38 sporadic SBAs. They found that expression of PD-L1 and PD-1 correlated with a number of clinico-pathological factors, such as the origin, microsatellite instability status, and tumor-infiltrating lymphocyte (TIL) density. The combined positive score (CPS) showed PD-L1 rates of 26% in the whole cohort of SBAs, with 35% in both celiac disease-SBAs and CrD-SBAs, compared with just 5% in sporadic SBAs. 

    Combined positive scores equal to or greater than 1 SBAs were found in 41% of MSI-H cases (41%), compared with just 18% of non-MSI-H cases; however, the team also found 15 CPS equal to or greater than 1 micro-satellite stable SBAs. CPS ≥ 1 SBAs showed higher TIL and PD-1+ immune cell density, more often medullary histotype, as well as a better outcome in comparison with CPS < 1 cases. 

    This study shows higher rates of PD-L1+ in both celiac disease-SBAs and CrD-SBAs compared with sporadic SBAs. Moreover, the discovery of a subset of PD-L1+ micro-satellite stable SBAs suggests that it will be beneficial to discover more biomarkers to immune checkpoint inhibitor response, along with MSI-H.

    Read more in Modern Pathology (2020)

     

    The research team included Paolo Giuffrida and Giovanni Arpa, Federica Grillo, Catherine Klersy, Gianluca Sampietro, Sandro Ardizzone, Paolo Fociani, Roberto Fiocca, Giovanni Latella, Fausto Sessa, Antonietta D’Errico, Deborah Malvi, Claudia Mescoli, Massimo Rugge, Gabriella Nesi, Stefano Ferrero, Daniela Furlan, Gilberto Poggioli, Fernando Rizzello, Maria C. Macciomei, Donatella Santini, Umberto Volta, Roberto De Giorgio, Giacomo Caio, Antonio Calabrò, Carolina Ciacci, Maria D’Armiento, Aroldo Rizzo, Gaspare Solina, Michele Martino, Francesco Tonelli, Vincenzo Villanacci, Renato Cannizzaro, Vincenzo Canzonieri, Ada M. Florena, Livia Biancone, Giovanni Monteleone, Roberto Caronna, Antonio Ciardi, Luca Elli, Flavio Caprioli, Maurizio Vecchi, Renata D’Incà, Fabiana Zingone, Anna D’Odorico, Marco Vincenzo Lenti, Barbara Oreggia, Luca Reggiani Bonetti, Marco Astegiano, Elena Biletta, Laura Cantoro, Antonino G. Giannone, Augusto Orlandi, Claudio Papi, Vittorio Perfetti, Erica Quaquarini, Giancarlo Sandri, Marco Silano, Paolo Usai, Valeria Barresi, Rachele Ciccocioppo, Ombretta Luinetti, Paolo Pedrazzoli, Andrea Pietrabissa, Alessandra Viglio, Marco Paulli, Gino R. Corazza, Enrico Solcia, Alessandro Vanoli & Antonio Di Sabatino.

    The researchers are variously affiliated with the Anatomic Pathology ASL Biella, Biella, Italy; the Department of Internal Medicine, University of Pavia and Fondazione IRCCS San Matteo Hospital, Pavia, Italy; the Anatomic Pathology Unit, Department of Molecular Medicine, University of Pavia and Fondazione IRCCS San Matteo Hospital, Pavia, Italy; the Department of Biopathology and Image Diagnostics, University of Tor Vergata, Rome, Italy; the Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Institute of Oncology and Transplant Pathology, University of Bologna, St. Orsola-Malpighi Hospital, Bologna, Italy; the Department of Internal Medicine, University of Pavia and Fondazione IRCCS San Matteo Hospital, Pavia, Italy; the Department of Gastroenterology, Centro di Riferimento Oncologico (CRO) di Aviano IRCCS, Aviano, Italy; the Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy; the Department of Medicine and Surgery, University of Salerno, Salerno, Italy; the Department of Systems Medicine, University of Tor Vergata, Rome, Italy; the Department of Surgical Sciences, La Sapienza University, Rome, Italy; the Department of Surgery, General Surgery II, University of Pavia and Fondazione IRCCS San Matteo Hospital, Pavia, Italy; the Department of Internal Medicine, University of Pavia and Fondazione IRCCS San Matteo Hospital, Pavia, Italy; the Department of Radiological, Oncological, Pathological Sciences, Umberto I Hospital, La Sapienza University, Rome, Italy; the; the Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy; the Gastroenterology Section, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy; the Gastroenterology Unit, USL Umbria 1, Perugia, Italy; the Pathologic Anatomy Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy; the General Surgery Unit, Ca’ Granda-Ospedale Maggiore Policlinico, Milan, Italy; the Section of Pathology, Department of Diagnostic Medicine and Public Health, University of Modena and Reggio Emilia, Modena, Italy; the General and Specialistic Surgery, Città della Salute e della Scienza-Molinette Hospital, Turin, Italy; the Gastroenterology Unit, Department of Medicine, AOUI Policlinico G.B. Rossi, University of Verona, Verona, Italy; the Department of Internal Medicine, University of Pavia and Fondazione IRCCS San Matteo Hospital, Pavia, Italy; the IBD Unit, San Filippo Neri Hospital, Rome, Italy; the Internal Medicine Unit, S.S. Annunziata Hospital, ASST-Pavia, Varzi, Italy Medical Oncology Unit, IRCCS ICS Maugeri and Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, Italy; the Oncology Unit, IRCCS San Matteo Hospital, Pavia, Italy; the Clinical Nutrition Unit, Sant’Eugenio Hospital, Rome, Italy; the Division of Pathology, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy; the Department of Diagnostics and Public Health, Section of Anatomical Pathology, University and Hospital Trust of Verona, Verona, Italy; the Department of Internal Medicine, University of Cagliari, Cagliari, Italy; the Pathology Unit of the Centro di Riferimento Oncologico (CRO) di Aviano IRCCS, Aviano, Italy; the Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy; the Pathology Unit of the Department of Surgical and Diagnostic Sciences, University of Genoa and San Martino/IST University Hospital, Genoa, Italy; the Biometry and Statistics Service, Fondazione IRCCS San Matteo Hospital, Pavia, Italy; the Surgery of the Alimentary Tract, Department of Medical and Surgical Sciences, Sant’Orsola—Malpighi Hospital, University of Bologna, Bologna, Italy; the Institute of Pathology, Spedali Civili Hospital, Brescia, Italy; the Pathologic Anatomy Unit, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy; the Pathology Unit, Department of Medicine and Surgery, University of Insubria, Varese, Italy; the Pathology Unit, San Camillo-Forlanini Hospital, Rome, Italy; the Public Health Department at Federico II University of Naples, Naples, Italy; the Department of Surgery and Translational Medicine, University of Florence, Florence, Italy; the Units of Pathology, Cervello Hospital, Palermo, Italy; the Units of General Surgery, Cervello Hospital, Palermo, Italy; the Unit of IBD Surgery, Luigi Sacco University Hospital, Milan, Italy; the Gastroenterology Unit, Luigi Sacco University Hospital, Milan, Italy; the Pathology Unit, Luigi Sacco University Hospital, Milan, Italy; and the Unit of Human Nutrition and Health, Istituto Superiore di Sanità, Rome, Italy.

    Edited by Scott Adams

    0

    User Feedback

    Recommended Comments

    There are no comments to display.



    Join the conversation

    You are posting as a guest. If you have an account, sign in now to post with your account.
    Note: Your post will require moderator approval before it will be visible.

    Guest
    Add a comment...

    ×   Pasted as rich text.   Restore formatting

      Only 75 emoji are allowed.

    ×   Your link has been automatically embedded.   Display as a link instead

    ×   Your previous content has been restored.   Clear editor

    ×   You cannot paste images directly. Upload or insert images from URL.


  • About Me

    Scott Adams was diagnosed with celiac disease in 1994, and, due to the nearly total lack of information available at that time, was forced to become an expert on the disease in order to recover. In 1995 he launched the site that later became Celiac.com to help as many people as possible with celiac disease get diagnosed so they can begin to live happy, healthy gluten-free lives.  He is co-author of the book Cereal Killers, and founder and publisher of the (formerly paper) newsletter Journal of Gluten Sensitivity. In 1998 he founded The Gluten-Free Mall which he sold in 2014. Celiac.com does not sell any products, and is 100% advertiser supported.


  • Celiac.com Sponsor (A17):
    Celiac.com Sponsor (A17):





    Celiac.com Sponsors (A17-m):




  • Related Articles

    Jefferson Adams
    Celiac.com 08/07/2015 - Actor Michael Douglass is making gluten-free celebrity news with his recent disclosure to ITV's Lorraine Kelly that he is eating gluten-free, and that he views the diet is an important part of his post-cancer health regimen.
    The 70-year old Oscar-winning actor says he feels "great," and credits the gluten-free diet with boosting his memory and transforming his health five years after cancer battle.
    Douglass recommends the diet and says it has helped him recover and maintain his weight after dropping over 40 pounds in his battle with throat cancer.
    The American actor, who stars in the superhero film Ant-Man, set for release...

    Jefferson Adams
    Celiac.com 03/12/2019 - Some doctors routinely conduct celiac testing in irritable bowel syndrome (IBS) patients, but it is not currently accepted practice.  A team of researchers recently set out to compare the rates of undiagnosed celiac disease in a large group of patients both with and without IBS.
    The research team included AE Almazar, NJ Talley, JJ Larson, EJ Atkinson, JA Murray, and YA Saito. They are variously affiliated with the Department of Medicine, the Division of Gastroenterology and Hepatology,  the Department of Health, Division of Biomedical Statistics and Informatics, and the Department of Immunology at the Mayo Clinic in Rochester, M...

    Jefferson Adams
    Celiac.com 9/26/2019 - Small bowel adenocarcinoma is a rare abnormal tissue growth, that can happen alone, or can also be the result of predisposing conditions, including hereditary syndromes and immune-mediated intestinal disorders, such as celiac disease. 
    However, researchers still don't know very much about small bowel adenocarcinoma in the context of celiac disease. To get some answers, a research team recently set out to show the main clinical features, diagnostic procedures and management options of small bowel adenocarcinoma cases detected in a large cohort of celiac patients diagnosed in a single tertiary care center.
    The research t...

    Jefferson Adams
    Celiac.com 03/11/2020 - Researchers don't have a very good understanding about the connection between symptoms, blood tests, and the results of small bowel capsule endoscopy (SBCE) in celiac patients. 
    Better understanding such connections will help to figure out whether symptoms and blood tests can determine the severity and extent of disease using SBCE. 
    A team of researchers recently set out determine if symptoms and blood tests can determine the severity and extent of disease using SBCE. The team included Stefania Chetcuti Zammit, David S. Sanders and Reena Sidhu, of the Academic Unit of Gastroenterology, Royal Hallamshire Hospital, S...